Macrophage targeting liposome and use thereof
Macrophage-targeting liposomes, composed of phospholipids, cationic polymers, and sterol-based compounds, address the challenge of selectively targeting macrophages to modulate their activity, offering an effective approach to treat inflammatory diseases by inducing M2 polarization and reducing inflammation.
Patent Information
- Application Number
- PCT/KR2023/007021
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
Current treatments lack effective methods to specifically target and control macrophage activity, which is implicated in various diseases such as atherosclerosis, neurodegenerative diseases, and inflammatory conditions, due to the inability to deliver drugs selectively to macrophages.
Development of macrophage-targeting liposomes comprising phospholipids, cationic polymers, and sterol-based compounds, with an average particle diameter of 500 nm or more, capable of specifically targeting macrophages through phagocytosis or micropinocytosis, and delivering nucleic acids to modulate macrophage polarization.
The macrophage-targeting liposomes effectively deliver nucleic acids to macrophages, inducing M2 polarization, thereby reducing inflammation and improving the treatment of inflammatory diseases by selectively targeting and modulating macrophage activity.
Smart Images

Figure KR2023007021_28112024_PF_FP_ABST
Abstract
Description
Macrophage-targeting liposomes and their uses
[0001] The present invention relates to macrophage-targeting liposomes and uses thereof.
[0002] Macrophages in the body are known to play a central role in the removal of foreign substances and waste products through phagocytosis and in innate immunity. Furthermore, they are also known to play a crucial role in the regulation of adaptive immunity through their antigen-processing function. However, in some cases, increased macrophage activity or function can lead to pathological conditions.
[0003] Diseases associated with the activation or function of macrophages include atherosclerosis, congestive heart failure, ischemic disease, restenosis, hypertension, fibrotic vascular disorders (e.g., diabetes, systemic lupus erythematosus), neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, spinocerebellar degeneration, amyotrophic lateral sclerosis, etc.), brain damage, cerebrovascular events (e.g., stroke, seizure, nerve injury, and regeneration within the central nervous system), hematopoietic disorders, adult respiratory distress syndrome (ARDS), cancer (especially leukemia including adult T-cell leukemia) and solid tumors, autoimmune diseases, infections (e.g., HIV infection and AIDS), fibroproliferative disorders (e.g., psoriasis), chronic and acute inflammatory diseases (e.g., rheumatoid arthritis, Crohn's disease, inflammatory bowel syndrome, etc.), glomerular diseases, sepsis, graft rejection, Examples include graft-versus-host disease, bone disease, cardiovascular and non-cardiovascular vascular conditions characterized by a dysplastic fibroblast / inflammatory response, and diseases characterized by leukocyte infiltration into damaged areas, such as those caused by oxygen- or glucose-deprived tissue (e.g., stroke and myocardial infarction).
[0004] Macrophages are also known as major inflammatory cells and exist as two types of macrophages through polarization. M1 macrophages have pro-inflammatory characteristics and take the form of inflammatory macrophages. Lipopolysaccharide (LPS) is a representative pathogenic substance known to induce macrophage-mediated inflammatory responses. It binds to TLR4 expressed on the surface of macrophages and triggers an inflammatory response through the secretion of inflammatory cytokines. In contrast, M2 macrophages, which have anti-inflammatory characteristics, are induced by cytokines such as IL-4 and IL-13 and secrete anti-inflammatory cytokines such as IL-10. Accordingly, they play a key role in resolving inflammation by maintaining homeostasis, such as wound healing and tissue remodeling. Therefore, controlling macrophage activity is crucial for treating the various diseases mentioned above, and to achieve this, a drug delivery system capable of delivering drugs specifically to macrophages is required.
[0005] Accordingly, the inventors of the present invention developed a liposome capable of specifically targeting macrophages and a delivery vehicle containing the same, thereby completing the present invention.
[0006] One aspect provides a liposome targeting macrophages, comprising a phospholipid, a cationic polymer, and a sterol compound, wherein the liposome has an average particle diameter of 500 nm or more.
[0007] Another aspect provides a macrophage-targeting nucleic acid delivery system comprising the macrophage-targeting liposome.
[0008] Another aspect provides a pharmaceutical composition for preventing or treating an inflammatory disease, comprising the macrophage-targeting liposome as an active ingredient.
[0009] Another aspect provides the use of a pharmaceutical composition comprising the macrophage-targeting liposome as an active ingredient for preventing or treating an inflammatory disease.
[0010] Another aspect provides a method for preventing or treating an inflammatory disease, comprising administering to a subject a pharmaceutical composition comprising the above macrophage-targeting liposome as an active ingredient.
[0011] One aspect is to provide a macrophage-targeting liposome comprising a phospholipid, a cationic polymer and a sterol compound, wherein the liposome has an average particle diameter of 500 nm or more.
[0012] As used herein, the term "liposome" refers to a vesicle enclosed by a fine spherical membrane, encompassing all compartments enclosed by a lipid bilayer. Liposomes possess an internal space, allowing them to transport drugs or other delivery substances. Furthermore, they can selectively absorb substances from their surroundings through their membrane, increasing their size. As their volume increases, they form and separate into smaller liposome droplets.
[0013] As used herein, the term "macrophage" or "phagocyte" is a type of white blood cell that is a major cell responsible for innate immunity. It is a type of white blood cell that performs phagocytosis, absorbing and digesting non-protein substances present in a healthy body, such as cell tissue, foreign substances, microorganisms, and cancer cells. Macrophages can induce or suppress inflammation in the body. When inflammation increases in the body or the immune system is stimulated, they work to suppress the inflammation in that area and can also release cytokines to reduce the immune response. Macrophages that induce inflammation are called M1 macrophages, and macrophages that reduce inflammation and promote tissue repair are called M2 macrophages.
[0014] The average particle diameter of the above macrophage-targeting liposome may be 700 nm or more, and specifically may be 700 nm or more, 1000 nm or more, 1500 nm or more, 2000 nm or more, 2500 nm or more, 3000 nm or more, or 3500 nm or more.
[0015] The average particle diameter of the macrophage-targeting liposome may be 700 to 5000 nm, specifically 700 to 5000 nm, 700 to 4500 nm, 700 to 4000 nm, 700 to 3500 nm, 700 to 3000 nm, 700 to 2500 nm, 700 to 2000 nm, 1000 to 5000 nm, 1000 to 4500 nm, 1000 to 4000 nm, 1000 to 3500 nm, 1000 to 3000 nm, 1000 to 2500 nm or 1000 to 2000 nm.
[0016] In one embodiment, as a result of examining whether liposomes manufactured in various sizes were specifically targeted to macrophages, it was confirmed that liposomes having an average particle diameter of about 400 nm did not specifically target macrophages, and that liposomes having an average particle diameter of about 750 nm or more showed improved macrophage-specific targeting efficiency compared to the control group.
[0017] The above macrophages may be one or more selected from the group consisting of adipose tissue macrophages, monocytes, Kupffer cells, sinus histiocytes, alveolar macrophages, Hofbauer cells, glomerular mesangial cells, microglia, Kupffer cells, and Langerhans cells.
[0018] The term "phospholipid" used herein refers to a type of lipid containing phosphorus, which is known as a major component of biological membranes along with glycolipids, cholesterol, and proteins. Phospholipids have a similar structure to fats, but unlike fats, which have three fatty acids bonded to glycerol, phospholipids differ in that two fatty acids and one phosphate group are bonded. The phosphate group is bonded to another organic substance, and the type of phospholipid varies depending on the type of organic substance bonded. Unlike fats, phospholipids are polar; the part where the fatty acid is located is hydrophobic and does not mix well with water but easily mixes with nonpolar substances, while the part where the phosphate group is located is hydrophilic and easily mixes with water molecules or other polar molecules.
[0019] The above phospholipids may constitute the bilayer of the liposome and may include natural phospholipids or synthetic phospholipids. The above phospholipids are phosphatidylcholine, egg yolk lecithin, hydrogenated lecithin, soy lecithin, lysolecithin, sphingomyelin, phosphatidic acid, phosphatidylinositol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol-4,5-diphosphate, cardiolipin, plasmalogen, dicetyl phosphate, distearoylphosphatidylcholine, dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylserine, eleostearoylphosphatidylcholine, eleostearoylphosphatidylethanolamine and It may include at least one selected from the group consisting of eleostearoylphosphatidylserine, and specifically, it may include at least one selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, phosphatidylinositol, and phosphatinylglycerol.
[0020] The term "sterol" or "sterol compound" used herein refers to one of the steroid compounds, which are found in most plants, animals, and fungi (fungi), and have important physiological functions in eukaryotic organisms. Among the sterols, cholesterol, which is found in animals, is known to be a major component of the cell membrane system along with ceramide and fatty acids in the stratum corneum structure.
[0021] The above sterol compound may include at least one selected from the group consisting of cholesterol, stigmasterol, campesterol, sitosterol, ergosterol, lanosterol, dinosterol, gorgosterol, avenasterol, saringosterol, and fucosterol, and may specifically include cholesterol.
[0022] The above phospholipid and sterol compounds may be included in a mass ratio of 40:0.8 to 40:10, and specifically, may be included in a mass ratio of 40:0.8 to 40:10, 40:0.8 to 40:8, 40:0.8 to 40:6, 40:1 to 40:10, 40:1 to 40:8, 40:1 to 40:6, 40:2 to 40:10, 40:2 to 40:8, or 40:2 to 40:6.
[0023] According to one embodiment, the macrophage-targeting liposome may comprise phosphatidylcholine and cholesterol, and specifically, the phosphatidylcholine and cholesterol may be comprised in a ratio of 40:3 to 40:6.
[0024] The cationic polymer may be at least one selected from the group consisting of polyethylenimine (PEI), polyamidoamine (PAA), poly-L-lysine (PLL), poly-D-lysine (PDL), protamine, poly[2-(N,N-dimethylamino)ethyl methacrylate] (PDMAEMA)), poly(amino-co-ester, PAE), chitosan, dextran, cationic gelatin, cationic cyclodextrin, and polypropylenimine, and may be specifically polyethylenimine, and more specifically branched polyethylenimine (bPEI).
[0025] The liposome comprises an internal space capable of encapsulating nucleic acids; and a lipid layer membrane surrounding the internal space, wherein the lipid layer comprises phospholipids and sterol compounds, and the cationic polymer may form a complex with the nucleic acid and be encapsulated in the internal space. The liposome is specifically targeted to macrophages, and can effectively deliver the nucleic acid to the macrophages.
[0026] The cationic polymer may form a complex with a nucleic acid molecule, and specifically, the cationic polymer may form a complex through electrostatic interaction with a negatively charged nucleic acid (gene) to stabilize the nucleic acid.
[0027] The nucleic acid comprises DNA or RNA, and the nucleic acid may be at least one selected from the group consisting of siRNA (small interfering RNA), shRNA (small hairpin RNA), esiRNA (endoribonuclease-prepared siRNAs), antisense oligonucleotides, DNA, single-stranded RNA, double-stranded RNA, DNA-RNA hybrid, microRNA (miRNA), and ribozyme, and specifically may be miRNA.
[0028] The nucleic acid and the cationic polymer may form a complex at a mass ratio of 1:0.3 to 1:6, and specifically, the complex may be formed at a mass ratio of 1:0.3 to 1:6, 1:0.3 to 1:5, 1:0.3 to 1:4, 1:0.3 to 1:3, 1:0.3 to 1:2, 1:0.5 to 1:6, 1:0.5 to 1:5, 1:0.5 to 1:4, 1:0.5 to 1:3, 1:0.5 to 1:2, 1:1 to 1:6, 1:1 to 1:5, 1:1 to 1:4, 1:1 to 1:3, or 1:1 to 1:2.
[0029] The nucleic acid and the cationic polymer may form a complex at an N / P ratio greater than 1, specifically, at an N / P ratio greater than 1, greater than 2, greater than 3, or greater than 5. In addition, the complex may be formed at a ratio less than 10.
[0030] The above macrophage-targeting liposomes may be internalized into macrophages via the mechanism of phagocytosis or micropinocytosis.
[0031] In one embodiment, the macrophage-targeting liposome comprises phosphatidylcholine, polyethyleneimine, cholesterol, and miRNA, wherein the phosphatidylcholine and cholesterol form a lipid layer membrane surrounding the internal space, and the polyethyleneimine and miRNA may form a complex and be encapsulated in the internal space. The liposome may be internalized by specifically targeting macrophages, and the miRNA within the liposome may be effectively delivered to the macrophages.
[0032] Another aspect is to provide a macrophage-targeting nucleic acid delivery system comprising the macrophage-targeting liposome. The same aspects described above also apply to the delivery system.
[0033] The above nucleic acid delivery vehicle may be one in which nucleic acid is encapsulated in the internal space of a liposome, and specifically, one in which a nucleic acid-cationic polymer complex is encapsulated.
[0034] The nucleic acid may be a miRNA, and may specifically include miR-10a, which induces M2 polarization of macrophages. The miR-10a may be represented by the base sequence of SEQ ID NO: 1.
[0035] Another aspect may be to provide a pharmaceutical composition comprising the macrophage-targeting liposome or the macrophage-targeting nucleic acid delivery vehicle as an active ingredient.
[0036] The pharmaceutical composition may comprise a nucleic acid that induces M2 polarization of macrophages, and may comprise at least one selected from the group consisting of miRNA-940, miRNA-1246, miRNA-148a, miRNA-21, miRNA-32, miRNA-124, and miR-10a, and may specifically comprise miR-10a.
[0037] The pharmaceutical composition specifically targets macrophages, and can deliver a nucleic acid that specifically induces M2 polarization to macrophages. Therefore, the pharmaceutical composition can effectively induce M2 polarization, thereby reducing the number of M1 macrophages that cause inflammation and increasing the number of M2 macrophages that reduce inflammation. Through this mechanism, the composition can exhibit anti-inflammatory efficacy.
[0038] The above pharmaceutical composition may be an anti-inflammatory composition or a composition for treating or preventing an inflammatory disease.
[0039] The term "anti-inflammation" in this specification means the process of causing inflammation or the property or efficacy of suppressing it, and the anti-inflammation may include improvement (alleviation of symptoms), treatment, prevention of inflammatory diseases, or suppression or delay in the onset of such diseases.
[0040] The term "inflammatory diseases" in this specification refers to a general term for diseases in which inflammation is the main lesion. The inflammatory diseases may be one or more of asthma, conjunctivitis, iritis, scleritis, uveitis, periodontitis, dermatitis, arthritis, degenerative arthritis, inflammatory bowel disease, ankylosing spondylitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastritis, nephritis, pancreatitis, hepatitis, tendonitis, and tenosynovitis. In addition, the inflammatory bowel disease may be a serious chronic inflammation caused by an inflammatory substance produced in the digestive tract, and specifically may include one or more selected from the group consisting of Crohn's disease, ulcerative colitis, Behcet's disease of the intestine, simple ulcer, radiation enteritis, and ischemic enteritis.
[0041] The pharmaceutical composition may include a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" may refer to a carrier or diluent that does not stimulate a living organism and does not inhibit the biological activity or properties of the injected compound. Here, "pharmaceutically acceptable" means that the carrier does not inhibit the activity of the active ingredient and does not exhibit toxicity exceeding the adaptability of the subject of application (prescription). Any carrier commonly used in the art and pharmaceutically acceptable for the pharmaceutical composition may be used. Non-limiting examples of the above carriers include lactose, dextrose, maltodextrin, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, glycerol, ethanol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, saline solution, sterile water, Ringer's solution, buffered saline, albumin injection solution, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil. These may be used alone or in combination of two or more. The pharmaceutical composition may be prepared as an oral formulation or a parenteral formulation according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient. The above pharmaceutical composition can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions, each according to a conventional method.
[0042] When formulating the above pharmaceutical composition, it may be prepared using a diluent or excipient such as a generally used filler, bulking agent, binder, wetting agent, disintegrant, or surfactant, but may not be limited thereto.
[0043] When the above pharmaceutical composition is manufactured into an oral dosage form, it can be manufactured into a dosage form such as powder, granules, tablets, pills, dragees, capsules, liquids, gels, syrups, suspensions, wafers, etc., using a suitable carrier according to a method known in the art. At this time, examples of suitable pharmaceutically acceptable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, xylitol, etc.; starches such as corn starch, potato starch, and wheat starch; celluloses such as cellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, and hydroxypropylmethylcellulose; polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyols, and vegetable oils. In case of formulation, the formulation may include diluents and / or excipients such as fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants, as needed.
[0044] When the above pharmaceutical composition is prepared as a parenteral dosage form, it can be formulated in the form of injections, transdermal administration, nasal inhalation, and suppositories using a suitable carrier according to a method known in the art. When formulated as an injection, suitable carriers include sterile water, ethanol, polyols such as glycerol or propylene glycol, or mixtures thereof, and preferably, Ringer's solution, phosphate buffered saline (PBS) containing triethanolamine, sterile water for injection, and isotonic solutions such as 5% dextrose can be used. When formulated as a transdermal dosage form, it can be formulated in the form of ointments, creams, lotions, gels, external solutions, pastes, liniments, aerosols, etc. In the case of nasal inhalation, it can be formulated in the form of an aerosol spray using a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, or carbon dioxide, and in the case of formulating it as a suppository, the base can be witepsol, tween 61, polyethylene glycol, cacao butter, laurin butter, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene stearate, sorbitan fatty acid ester, etc.
[0045] The pharmaceutical composition may be administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" refers to an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention, and the effective dosage level may be determined based on factors including the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration of the composition of the present invention used, the route of administration and the excretion rate, the treatment period, drugs used in combination or simultaneously with the composition of the present invention used, and other factors well known in the medical field. The pharmaceutical composition of the present invention may be administered alone or in combination with a known anti-inflammatory or inflammatory disease-treating ingredient. It is important to take all of the above factors into consideration and administer an amount that can achieve the maximum effect with the minimum amount without side effects.
[0046] The dosage of the pharmaceutical composition may be determined by a person skilled in the art in consideration of the intended use, the degree of toxicity of the disease, the patient's age, weight, sex, medical history, or the type of substance used as the active ingredient. For example, the pharmaceutical composition of the present invention may be administered at about 0.1 ng to about 1,000 mg / kg, preferably 1 ng to about 100 mg / kg, per adult, and the frequency of administration of the composition of the present disclosure is not particularly limited thereto, but may be administered once a day or administered in divided doses several times. The dosage or frequency of administration does not limit the scope of the present disclosure in any way.
[0047] Another aspect provides the use of a pharmaceutical composition comprising a macrophage-targeting liposome as an active ingredient for preventing or treating an inflammatory disease. The inflammatory disease and the liposome are as described above.
[0048] Another aspect provides a method for preventing or treating an inflammatory disease, comprising administering to a subject a pharmaceutical composition comprising the above-described macrophage-targeting liposome as an active ingredient. The inflammatory disease and the liposome are as described above.
[0049] A macrophage-targeting liposome and a nucleic acid delivery system comprising the same according to one aspect can specifically target macrophages, and thus have the advantage of being able to effectively deliver a drug for regulating the physiological activity of macrophages.
[0050] Figure 1a is a graph showing the sizes of liposomes produced with various composition ratios, and Figure 1b is an image showing the macrophage targeting efficiency of liposomes of various sizes.
[0051] Figure 2a is an image showing the ability to form a complex with miRNA according to the type and composition ratio of cationic polymers, Figure 2b is an image showing the ability to form a complex according to the N / P ratio of PEI-miRNA complexes, and Figure 2c is a graph showing the cytotoxicity according to the N / P ratio of PEI-miRNA complexes.
[0052] Figures 3a and 3b are graphs showing the size and surface charge of macrophage-targeting liposomes loaded with PEI-miRNA complexes, Figure 3c is a graph showing the encapsulation efficiency of PEI-miRNA complexes, Figure 3d is an electron microscope image of macrophage-targeting liposomes loaded with PEI-miRNA complexes, and Figure 3e is an image showing whether or not the macrophage-targeting liposomes loaded with PEI-miRNA complexes are targeted to macrophages.
[0053] Figures 4a, 4b, and 4c are graphs and images showing the macrophage-specific targeting efficiency and miRNA delivery efficiency of macrophage-targeting liposomes loaded with PEI-miRNA complexes.
[0054] Figures 5a and 5b are graphs showing the internalization efficiency of macrophage-targeting liposomes according to treatment with various cell internalization mechanism inhibitors, and Figure 5c is an image of the macrophage-targeting liposome endocytosis process observed using a confocal microscope.
[0055] Figures 6a, 6b, and 6c are images and graphs confirming at the cellular level whether M2 polarization is induced by treatment with macrophage-targeting liposomes loaded with miR-10a.
[0056] Figures 7a, 7b, and 7c are graphs that confirm at the animal level whether M2 polarization is induced by treatment with macrophage-targeting liposomes loaded with miR-10a.
[0057] The present invention will be described in more detail through the following examples. However, these examples are provided for illustrative purposes only and the scope of the present invention is not limited to these examples.
[0058] Example 1. Production of liposomes of various sizes and analysis of macrophage targeting according to liposome size.
[0059] To produce liposomes that specifically target macrophages, liposomes of various sizes were first produced and the following experiments were performed to determine the macrophage targeting effect according to size.
[0060] Specifically, liposomes were prepared by controlling the ratio of cholesterol and centrifugation speed, and the prepared liposomes were analyzed using a nanoparticle size analyzer. First, 100 mg / mL of phosphatidylcholine and 10 mg / mL of cholesterol were dissolved in ethanol to prepare them. The two lipid solutions were mixed so that the mass ratios of phosphatidylcholine and cholesterol were 40:0.75, 40:3, and 40:6, respectively. Then, all the ethanol was evaporated using an evaporator at 40 °C and 150 rpm. After sufficient chloroform was added to completely redisperse the solution, all the chloroform was evaporated at 40 °C and 150 rpm to form a lipid film. PBS was added, and a water bath sonicator was used to ensure complete and uniform hydration, and the lipid film was hydrated at room temperature at 100 rpm for 2 hours. Liposome particles were obtained by centrifuging at 8000 rpm, 10°C for 20 minutes using a centrifuge, removing the supernatant, and redispersing in PBS, repeating this process twice.
[0061] As a result of analyzing the liposomes produced above using a nanoparticle size analyzer, particles with sizes of 392 nm, 750 nm, and 3502 nm (approximately 400 to 3500 nm) were successfully produced. Therefore, it is understood that liposomes of various sizes can be produced if the cholesterol concentration is refined and produced (Fig. 1A).
[0062] Next, to confirm the macrophage targeting efficacy of the liposomes produced above, the liposomes were treated with RAW 264.7 cells, a macrophage cell line, and HEK293T cells as a control. The liposomes were stained with a fluorescent dye prior to treatment.
[0063] After treating cells with liposomes of various sizes, 4 hours later, fluorescence microscopy confirmed that liposomes were delivered specifically to macrophages as the size of the liposome particles increased (Fig. 1B). Therefore, based on these results, it can be seen that larger liposomes can specifically target macrophages.
[0064] Example 2. Production of liposome-based miRNA delivery system
[0065] 2.1. Selection of polymers and composition ratios for miRNA-polymer complex formation
[0066] To fabricate a liposome-based miRNA delivery system, the following experiments were first performed to construct a miRNA-polymer complex for efficiently encapsulating miRNA inside liposomes.
[0067] Specifically, to develop miRNA-polymer complexes with excellent encapsulation efficiency, complexes were prepared by binding various cationic polymers to miRNA at various mass ratios as shown in the table. The formed complexes were loaded onto a 1% agarose gel, and the complex formation ability of each cationic polymer and miRNA was confirmed through electrophoresis (if a complex was formed, electrophoresis did not proceed and the complex remained in the well).
[0068] As a result, when bPEI 25 kDa was used as a cationic polymer, a complete complex was formed when the mass ratio of miRNA to PEI was 1:0.333 or higher. Protamine formed a complete complex when the mass ratio was 1:1.665 or higher, and it was confirmed that Poly-D-lysine did not form a complete complex even at 1:6.66 (Fig. 2A). Therefore, it was found that bPEI 25 kDa was the cationic polymer that formed a complex with miRNA with the highest efficiency.
[0069] Next, using PEI, the polymer that most efficiently formed complexes, the complex formation ability was confirmed by loading it onto an agarose gel at various N / P ratios under high concentration conditions. As a result, it was confirmed that almost all complexes were formed at N / P 1 or higher, and that complete complex formation occurred from N / P 5 or higher (miRNA:PEI = 1:1.665).
[0070] Next, cytotoxicity was assessed using the CCK-8 kit under conditions of fully complexed N / P 5 or higher. The results confirmed that toxicity was dependent on the amount of PEI (Fig. 2C). Therefore, we attempted to encapsulate the N / P 5 complex, which exhibited the least toxicity, into liposomes.
[0071] 2.2. Confirmation of the encapsulation efficiency of miRNA-polymer complexes
[0072] To confirm the macrophage-targeting liposome encapsulation efficiency of the miRNA-polymer complex confirmed in Example 2.1 above, the following experiment was performed.
[0073] Specifically, to prepare liposomes loaded with miR-FAM, a fluorescently labeled miRNA, 1 mg / mL of PEI and 1 ug / uL of miRNA were prepared using distilled water. The miRNA and PEI were mixed at a mass ratio of 1:1.65 and reacted at room temperature for 20 minutes to form a complex. 10 mg / mL of liposomes dispersed in PBS were added to the complex at a ratio of 50 uL per 1 ug of miRNA, and the complex was reacted at room temperature for 5 minutes. After repeating rapid freezing and slow thawing four times for 4 minutes each, the mixture was centrifuged at 4°C, 8000 rpm, for 20 minutes, followed by removal of the supernatant and redispersion in PBS twice to obtain macrophage-targeting liposomes loaded with miRNA-polymer complexes. As a control, macrophage-targeting liposomes loaded with miRNA alone were prepared. In addition, to confirm the characteristics of the above-mentioned manufactured liposomes, they were analyzed using a nanoparticle size analyzer and a plate reader, and to confirm the macrophage targeting efficiency, macrophage RAW 264.7 cells were treated with liposomes encapsulating miRNA and liposomes encapsulating polymer-miRNA complexes (2 mg / well based on liposomes), and 4 hours after treatment, cell internalization was evaluated using a fluorescence microscope.
[0074] As a result of evaluating the physical properties such as size and surface charge of the macrophage-targeting liposomes (MT Lipo-COM) encapsulating miRNA-polymer complexes, the size of the liposome encapsulating only miRNA (MT Lipo-miR-FAM) was measured to be 2883 nm, and the size of the liposome encapsulating PEI-miRNA was measured to be 2434 nm, respectively (Fig. 3A). In addition, as a result of measuring the surface charge, the surface charge of the liposome encapsulating only miRNA was measured to be -11.89 mV, and the surface charge of the liposome encapsulating PEI-miRNA was measured to be -7.69 mV (Fig. 3B), so it can be considered that when miRNA was encapsulated using the cationic polymer PEI, the cationic polymer affected the surface charge of the liposome.
[0075] Next, we analyzed the encapsulation efficiency of miRNA according to the presence or absence of complex formation with PEI, and confirmed that the encapsulation efficiency in the case of PEI-miRNA complex was significantly increased compared to the control group in which miRNA alone was encapsulated (Fig. 3C). Specifically, when only miRNA was encapsulated in liposomes, most miRNAs were not encapsulated inside the liposomes, but when complexed with PEI, the efficiency increased, and it was confirmed that approximately 70-80% of miRNAs were successfully encapsulated in the liposomes. In addition, the liposomes encapsulated with PEI-miRNA complexes were analyzed using scanning electron microscopy and transmission electron microscopy, and the round shape and lipid bilayer appearance of the fabricated liposomes were confirmed (Fig. 3D).
[0076] Next, after treating RAW 264.7 cells with PEI-miRNA-encapsulated macrophage-targeting liposomes, the fluorescence of internalized miR-FAM was observed. In the group treated with liposomes encapsulating only miRNA without PEI, almost no fluorescence was observed, whereas when liposomes encapsulating PEI-miRNA complexes were treated, green fluorescence was observed inside the cells (Fig. 3E). Based on the above results, it can be seen that the PEI-miRNA complex is efficiently encapsulated in the macrophage-targeting liposomes of the present invention and that the delivery efficiency to macrophages is also excellent.
[0077] Example 4. Confirmation of macrophage-specific targeting and delivery efficiency
[0078] To confirm the macrophage-specific targeting and delivery efficiency of the macrophage-targeting liposome encapsulating the PEI-miRNA complex produced in Example 3, the following experiments were performed.
[0079] Specifically, RAW 264.7 cells, a representative macrophage cell line, and HEK293T cells as a control were treated with the MT Lipo-COM liposomes prepared above at a standard of 2 ug of miRNA, and 4 hours after treatment, the cellular internalization of miRNA was evaluated using a fluorescence microscope and flow cytometer.
[0080] Observation of the above cells under a fluorescence microscope confirmed that clear green fluorescence was observed in RAW264.7 cells, but no fluorescence signal was observed at all in HEK293T cells (Fig. 4A). In addition, flow cytometry analysis results confirmed that MT Lipo-COM exhibited a fluorescence signal of 43.63% in RAW264.7 cells, but only 9.44% in HEK293T cells (Fig. 4B and C). Therefore, based on the above results, it can be seen that the macrophage-targeting liposome of the present invention has remarkably excellent specific targeting efficiency and delivery efficiency.
[0081] Example 5. Confirmation of the delivery mechanism of macrophage-targeting liposomes.
[0082] To confirm the macrophage targeting and internalization mechanism of macrophage-targeting liposomes, the following experiments were performed.
[0083] Specifically, in order to observe the change in the internalization rate after treating the macrophage-targeting liposomes to cells after treating them with various inhibitors related to the cellular internalization mechanism, the cells were pretreated with CytoD, Amiloride, CPZ, MβCD, and Dynasore, which are inhibitors known to inhibit phagocytosis, micropinocytosis, clathrin-coated vesicles, caveolin-coated vesicles, and clathrin- and caveolin-coated vesicles, respectively, for 1 hour before treating the miRNA-encapsulated liposomes, and the cellular internalization from 0 to 6 hours after liposome treatment was observed using a flow cytometer and a confocal fluorescence microscope.
[0084] As a result, it was confirmed that the cellular internalization efficiency of macrophage-targeting liposomes was significantly reduced when treated with CytoD and Alimoride compared to the control group (Fig. 5A and B). Based on the above results, it can be seen that the macrophage-targeting liposomes of the present invention are internalized into macrophages through phagocytosis and macropinocytosis mechanisms and deliver miRNA.
[0085] Next, the endocytosis process of macrophage-targeting liposomes was observed over time using a confocal microscope (macrophage-targeting liposomes encapsulating fluorescently labeled miRNA are shown in green, and endosomes are labeled with LAMP1 and shown in red). As a result, only endosomes were observed for up to 1 hour after liposome treatment, but after 2 to 4 hours, colocalization of endosomes and macrophage-targeting liposomes was observed, and after 6 hours, numerous liposomes were observed in the cytoplasm (Fig. 5C). Based on the above results, it can be seen that macrophage-targeting liposomes encapsulating miRNA are internalized into cells through endocytosis and ultimately escape from the endosomes, effectively delivering miRNA into the cytoplasm.
[0086] Example 6. Evaluation of Macrophage Polarization Efficiency Using Macrophage-Targeting Liposomes - Cell Experiment
[0087] To determine at the cellular level whether macrophage polarization can be induced using macrophage-targeting liposomes, the following experiments were performed.
[0088] Specifically, we constructed a macrophage-targeting liposome (MT Lipo-COM) encapsulating miR-10a (SEQ ID NO: 1), known to induce M2 polarization of macrophages, in the form of a complex with PEI. The liposome was then treated to RAW 264.7 cells, which were induced to polarize toward M1 by LPS treatment, to induce M2 polarization. RNA or protein was then obtained from the cells, and the expression levels of M1 and M2 markers were confirmed using RT-PCR and Western blotting, respectively. In addition, IL-4, a cytokine known to promote the activation of macrophages into M2 cells and inhibit their polarization toward M1, was treated and used as a positive control. The sequences of the primer sets used in the RT-PCR are shown in Table 1 below.
[0089] Gene sequence (5' - 3') Size (bp) SEQ ID NOSForwardTTCACCCAGTTGTGCATCGACCTA1622ReverseTCCATGGTCACCTCCAACACAAGA3Socs3ForwardCTTTGTAGACTTCACGGCTGCC2324ReverseGGGAAACTTGCTGTGGGTGA5Arg1ForwardAACACGGCAG TGGCTTTAACC1326ReverseGGTTTTCATGTGGCGCATTC7Mrc1ForwardCTGGATTGGACTCAACAGTCTGA1618ReverseCCAGATTTTCCCACTTGGC9Rpl7ForwardTCAATGGAGTAAGCCCAAA24610ReverseCAAGAGACCGAGCAATCAAG11
[0090] When marker expression levels were confirmed at the mRNA level using RT-PCR, M1 markers increased while M2 markers decreased after LPS treatment. Compared to the control group (macrophage-targeting liposome without miR-10a loading, MT-Lipo), treatment with cell-targeting liposomes loaded with miR-10a-PEI complexes decreased the expression levels of M1 markers iNOS and Socs3, similar to the positive control group treated with IL-4, whereas the expression levels of M2 markers Arg1 and Mrc1 increased (Fig. 6A and B). In addition, when marker expression levels were confirmed at the protein level using Western blotting, similar to the results at the mRNA level, treatment with cell-targeting liposomes loaded with miR-10a decreased the expression of M1 markers p-p65, p65, and iNOS, while increasing the expression of M2 markers ARG1 and CD206 (Fig. 6C).
[0091] Based on the above results, it can be seen that the macrophage-targeting liposomes of the present invention can not only effectively deliver encapsulated miRNA, but also that the delivered miRNA can exhibit excellent physiological activity within the cell. Furthermore, it can be seen that the macrophage-targeting liposomes loaded with miR-10a can suppress inflammation by inducing M2 polarization of macrophages.
[0092] Example 7. Evaluation of Macrophage Polarization Efficiency Using Macrophage-Targeting Liposomes - Animal Experiment
[0093] To confirm at the animal level whether polarization of macrophages can be induced using the macrophage-targeting liposome of the present invention, the following experiments were performed.
[0094] Specifically, M1 polarization of splenic macrophages was induced in a mouse model by intraperitoneal LPS injection (5 mg / kg). 12 and 24 h after LPS injection, macrophage-targeting liposomes loaded with miR-10a were intravenously injected once each. 24 h after injection, spleens were extracted, and macrophages were sorted using flow cytometry, and polarization was evaluated.
[0095] As a result, when macrophage-targeting liposomes loaded with miR-10a-PEI complexes were treated in LPS-injected mice, the number of M2 polarized macrophages was confirmed to have significantly increased compared to the control group (macrophage-targeting liposomes without miR-10a, MT-Lipo) (Fig. 7A). In addition, when the ratio of M1 / M2 macrophages in total macrophages was confirmed, in the control group treated with MT-Lipo, M1 and M2 polarized macrophages were 79.4% and 20.6%, respectively, but in the group treated with the macrophage-targeting liposomes, they were confirmed to be 67.1% and 32.9%, respectively, confirming a significant increase in the number of M2 polarized macrophages (Fig. 7B). The above results may imply that macrophage-targeting liposomes loaded with miR-10a-PEI complexes repolarize macrophages polarized to M1 by LPS to M2.
[0096] Next, to confirm that the macrophage-targeting liposomes loaded with the miR-10a-PEI complex of the present invention do not affect other immune cells, we evaluated the population changes of neutrophils, NK cells, T cells, and B cells in mice injected with LPS. As a result, we confirmed that treatment with MT-Lipo or the liposomes did not change the immune cell population compared to the negative control (Fig. 7C). This indicates that the macrophage-targeting liposomes effectively target macrophages in vivo and therefore will not affect the population changes of other immune cells.
[0097] In summary, the above results show that miRNA-encapsulated macrophage-targeting liposomes specifically target macrophages even under in vivo conditions, and that the polarization of macrophages can be effectively controlled by the delivered miRNA.
[0098] The foregoing description of the present invention is provided for illustrative purposes only. Those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.
Claims
1. A macrophage-targeting liposome comprising a phospholipid, a cationic polymer, and a sterol compound, A liposome having an average particle diameter of 1000 nm or more.
2. A liposome according to claim 1, wherein the phospholipid comprises at least one selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, cardiolipin, phosphatidylinositol, and phosphatidylglycerol.
3. A liposome according to claim 1, wherein the cationic polymer comprises at least one selected from the group consisting of polyethylenimine (PEI), polyamidoamine (PAA), poly-L-lysine (PLL), poly-D-lysine (PDL), protamine, poly[2-(N,N-dimethylamino)ethyl methacrylate] (PDMAEMA), poly(amino-co-ester, PAE), chitosan, dextran, cationic gelatin, cationic cyclodextrin, and polypropylenimine.
4. A liposome according to claim 1, wherein the sterol compound comprises at least one selected from the group consisting of cholesterol, stigmasterol, campesterol, sitosterol, ergosterol, lanosterol, dinosterol, gorgosterol, avenasterol, saringosterol, and fucosterol.
5. In claim 1, the liposome comprises an internal space capable of encapsulating nucleic acid; and a lipid layer membrane surrounding the internal space. The above lipid layer comprises phospholipids and sterol compounds, A liposome in which the cationic polymer forms a complex with nucleic acid and is encapsulated in the internal space.
6. A liposome according to claim 5, wherein the nucleic acid and the cationic polymer form a complex at an N / P ratio greater than 1.
7. A macrophage-targeting nucleic acid delivery vehicle comprising a liposome according to any one of claims 1 to 6.
8. A pharmaceutical composition for preventing or treating an inflammatory disease, comprising the macrophage-targeting liposome of any one of claims 1 to 6 as an active ingredient.
9. Use of a pharmaceutical composition comprising the liposome of any one of claims 1 to 6 as an active ingredient for preventing or treating an inflammatory disease.
10. A method for preventing or treating an inflammatory disease, comprising administering to a subject a pharmaceutical composition comprising the liposome of any one of claims 1 to 6 as an active ingredient.
Citation Information
Patent Citations
Lipid coatings for implantable medical devices
US20090099651A1
Gene therapy products
WO2000074724A2
Compositions and methods for treating lung diseases and lung injury
WO2017008076A1
Cited By
Treatment and prevention of hemophilic arthropathy with mir10a
WO2026169334A1
